| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | steroid 11-beta-monooxygenase activity | 1.16e-06 | 2 | 22 | 2 | GO:0004507 | |
| GeneOntologyMolecularFunction | corticosterone 18-monooxygenase activity | 1.16e-06 | 2 | 22 | 2 | GO:0047783 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen | 8.97e-05 | 13 | 22 | 2 | GO:0016713 | |
| GeneOntologyMolecularFunction | steroid hydroxylase activity | 6.36e-04 | 34 | 22 | 2 | GO:0008395 | |
| GeneOntologyBiologicalProcess | regulation of blood volume by renal aldosterone | 7.13e-06 | 4 | 23 | 2 | GO:0002017 | |
| GeneOntologyBiologicalProcess | tertiary alcohol biosynthetic process | 5.32e-05 | 10 | 23 | 2 | GO:1902645 | |
| GeneOntologyBiologicalProcess | cortisol biosynthetic process | 5.32e-05 | 10 | 23 | 2 | GO:0034651 | |
| GeneOntologyBiologicalProcess | aldosterone biosynthetic process | 6.50e-05 | 11 | 23 | 2 | GO:0032342 | |
| GeneOntologyBiologicalProcess | cortisol metabolic process | 7.80e-05 | 12 | 23 | 2 | GO:0034650 | |
| GeneOntologyBiologicalProcess | mineralocorticoid biosynthetic process | 9.21e-05 | 13 | 23 | 2 | GO:0006705 | |
| GeneOntologyBiologicalProcess | primary alcohol biosynthetic process | 1.07e-04 | 14 | 23 | 2 | GO:0034309 | |
| GeneOntologyBiologicalProcess | aldosterone metabolic process | 1.07e-04 | 14 | 23 | 2 | GO:0032341 | |
| GeneOntologyBiologicalProcess | mineralocorticoid metabolic process | 1.60e-04 | 17 | 23 | 2 | GO:0008212 | |
| GeneOntologyBiologicalProcess | glucocorticoid biosynthetic process | 1.80e-04 | 18 | 23 | 2 | GO:0006704 | |
| GeneOntologyBiologicalProcess | drinking behavior | 1.80e-04 | 18 | 23 | 2 | GO:0042756 | |
| GeneOntologyBiologicalProcess | renal system process involved in regulation of blood volume | 1.80e-04 | 18 | 23 | 2 | GO:0001977 | |
| GeneOntologyBiologicalProcess | tertiary alcohol metabolic process | 2.71e-04 | 22 | 23 | 2 | GO:1902644 | |
| GeneOntologyBiologicalProcess | regulation of systemic arterial blood pressure by circulatory renin-angiotensin | 2.97e-04 | 23 | 23 | 2 | GO:0001991 | |
| GeneOntologyBiologicalProcess | C21-steroid hormone biosynthetic process | 3.80e-04 | 26 | 23 | 2 | GO:0006700 | |
| GeneOntologyBiologicalProcess | glucocorticoid metabolic process | 4.10e-04 | 27 | 23 | 2 | GO:0008211 | |
| GeneOntologyBiologicalProcess | positive regulation of systemic arterial blood pressure | 4.42e-04 | 28 | 23 | 2 | GO:0003084 | |
| GeneOntologyBiologicalProcess | aldehyde biosynthetic process | 5.42e-04 | 31 | 23 | 2 | GO:0046184 | |
| GeneOntologyBiologicalProcess | renal system process involved in regulation of systemic arterial blood pressure | 5.42e-04 | 31 | 23 | 2 | GO:0003071 | |
| GeneOntologyBiologicalProcess | olefinic compound biosynthetic process | 6.92e-04 | 35 | 23 | 2 | GO:0120255 | |
| GeneOntologyBiologicalProcess | regulation of systemic arterial blood pressure by renin-angiotensin | 7.74e-04 | 37 | 23 | 2 | GO:0003081 | |
| GeneOntologyBiologicalProcess | C21-steroid hormone metabolic process | 1.14e-03 | 45 | 23 | 2 | GO:0008207 | |
| GeneOntologyBiologicalProcess | steroid hormone biosynthetic process | 1.47e-03 | 51 | 23 | 2 | GO:0120178 | |
| GeneOntologyBiologicalProcess | regulation of systemic arterial blood pressure by hormone | 1.47e-03 | 51 | 23 | 2 | GO:0001990 | |
| GeneOntologyBiologicalProcess | ketone biosynthetic process | 1.83e-03 | 57 | 23 | 2 | GO:0042181 | |
| GeneOntologyBiologicalProcess | positive regulation of blood pressure | 1.96e-03 | 59 | 23 | 2 | GO:0045777 | |
| GeneOntologyBiologicalProcess | regulation of systemic arterial blood pressure mediated by a chemical signal | 2.09e-03 | 61 | 23 | 2 | GO:0003044 | |
| GeneOntologyCellularComponent | presynaptic active zone | 4.82e-04 | 141 | 23 | 3 | GO:0048786 | |
| GeneOntologyCellularComponent | glutamatergic synapse | 1.69e-03 | 817 | 23 | 5 | GO:0098978 | |
| GeneOntologyCellularComponent | presynaptic active zone membrane | 3.31e-03 | 78 | 23 | 2 | GO:0048787 | |
| HumanPheno | Elevated serum 11-deoxycortisol | 8.33e-07 | 9 | 12 | 3 | HP:0025436 | |
| HumanPheno | Secretory adrenocortical adenoma | 1.52e-05 | 3 | 12 | 2 | HP:0011746 | |
| HumanPheno | Neoplasm of the adrenal cortex | 3.17e-05 | 28 | 12 | 3 | HP:0100641 | |
| HumanPheno | Increased circulating cortisol level | 4.77e-05 | 32 | 12 | 3 | HP:0003118 | |
| HumanPheno | Increased circulating aldosterone concentration | 4.77e-05 | 32 | 12 | 3 | HP:0000859 | |
| HumanPheno | Dexamethasone-suppressible primary hyperaldosteronism | 5.07e-05 | 5 | 12 | 2 | HP:0011739 | |
| HumanPheno | Abnormality of aldosterone production | 1.25e-04 | 44 | 12 | 3 | HP:0002855 | |
| HumanPheno | Neoplasm of the adrenal gland | 1.53e-04 | 47 | 12 | 3 | HP:0100631 | |
| HumanPheno | Adrenocortical adenoma | 1.81e-04 | 9 | 12 | 2 | HP:0008256 | |
| HumanPheno | Abnormal circulating aldosterone concentration | 1.95e-04 | 51 | 12 | 3 | HP:0040085 | |
| HumanPheno | Increased circulating androstenedione concentration | 2.27e-04 | 10 | 12 | 2 | HP:0025380 | |
| HumanPheno | Primary hyperaldosteronism | 2.27e-04 | 10 | 12 | 2 | HP:0011736 | |
| HumanPheno | Abnormality of renin-angiotensin system | 2.45e-04 | 55 | 12 | 3 | HP:0000847 | |
| HumanPheno | Adrenal overactivity | 2.45e-04 | 55 | 12 | 3 | HP:0002717 | |
| HumanPheno | Abnormal circulating androstenedione concentration | 2.77e-04 | 11 | 12 | 2 | HP:0033811 | |
| HumanPheno | Abnormality of circulating cortisol level | 4.20e-04 | 66 | 12 | 3 | HP:0011731 | |
| HumanPheno | Abnormality of circulating glucocorticoid level | 4.40e-04 | 67 | 12 | 3 | HP:0012111 | |
| HumanPheno | Caesarian section | 5.25e-04 | 15 | 12 | 2 | HP:0011410 | |
| HumanPheno | Adrenocortical abnormality | 6.62e-04 | 77 | 12 | 3 | HP:0000849 | |
| HumanPheno | Hypokalemia | 7.14e-04 | 79 | 12 | 3 | HP:0002900 | |
| HumanPheno | Increased circulating androgen concentration | 7.62e-04 | 18 | 12 | 2 | HP:0030348 | |
| HumanPheno | Abnormal urine hormone level | 8.51e-04 | 19 | 12 | 2 | HP:0012029 | |
| HumanPheno | Decreased circulating aldosterone concentration | 8.51e-04 | 19 | 12 | 2 | HP:0004319 | |
| MousePheno | abnormal urine progesterone level | 1.94e-06 | 2 | 20 | 2 | MP:0011545 | |
| MousePheno | abnormal urine deoxycorticosterone level | 1.94e-06 | 2 | 20 | 2 | MP:0011552 | |
| MousePheno | decreased urine corticosterone level | 1.94e-06 | 2 | 20 | 2 | MP:0011550 | |
| MousePheno | increased urine deoxycorticosterone level | 1.94e-06 | 2 | 20 | 2 | MP:0011553 | |
| MousePheno | increased urine progesterone level | 1.94e-06 | 2 | 20 | 2 | MP:0011546 | |
| MousePheno | decreased urine aldosterone level | 1.16e-05 | 4 | 20 | 2 | MP:0011541 | |
| MousePheno | abnormal urine aldosterone level | 1.16e-05 | 4 | 20 | 2 | MP:0011539 | |
| MousePheno | abnormal adrenal gland zona glomerulosa morphology | 1.16e-05 | 4 | 20 | 2 | MP:0008293 | |
| MousePheno | abnormal urine corticosterone level | 1.16e-05 | 4 | 20 | 2 | MP:0011548 | |
| MousePheno | decreased urine hormone level | 1.16e-05 | 4 | 20 | 2 | MP:0014459 | |
| MousePheno | increased adrenal gland zona fasciculata size | 1.94e-05 | 5 | 20 | 2 | MP:0014286 | |
| MousePheno | uterus adenomyosis | 2.91e-05 | 6 | 20 | 2 | MP:0009221 | |
| MousePheno | increased urine hormone level | 2.91e-05 | 6 | 20 | 2 | MP:0014458 | |
| MousePheno | adrenal gland hyperplasia | 2.91e-05 | 6 | 20 | 2 | MP:0009078 | |
| MousePheno | increased brain weight | 3.20e-05 | 44 | 20 | 3 | MP:0002176 | |
| MousePheno | abnormal urine hormone level | 4.07e-05 | 7 | 20 | 2 | MP:0011538 | |
| MousePheno | pituitary gland hyperplasia | 4.07e-05 | 7 | 20 | 2 | MP:0000635 | |
| MousePheno | abnormal brain weight | 5.12e-05 | 148 | 20 | 4 | MP:0012775 | |
| MousePheno | increased circulating angiotensin II level | 5.42e-05 | 8 | 20 | 2 | MP:0031232 | |
| MousePheno | increased angiotensin II level | 5.42e-05 | 8 | 20 | 2 | MP:0031229 | |
| MousePheno | decreased circulating renin level | 8.69e-05 | 10 | 20 | 2 | MP:0003353 | |
| MousePheno | abnormal adrenocortical cell morphology | 8.69e-05 | 10 | 20 | 2 | MP:0008291 | |
| MousePheno | abnormal adrenal gland zona fasciculata size | 1.06e-04 | 11 | 20 | 2 | MP:0014284 | |
| MousePheno | uterus cyst | 1.06e-04 | 11 | 20 | 2 | MP:0009082 | |
| MousePheno | hypokalemia | 1.27e-04 | 12 | 20 | 2 | MP:0004119 | |
| MousePheno | enlarged pituitary gland | 1.27e-04 | 12 | 20 | 2 | MP:0000636 | |
| MousePheno | abnormal circulating angiotensin II level | 1.27e-04 | 12 | 20 | 2 | MP:0031230 | |
| MousePheno | abnormal angiotensin II level | 1.27e-04 | 12 | 20 | 2 | MP:0031227 | |
| MousePheno | increased renin activity | 1.75e-04 | 14 | 20 | 2 | MP:0005582 | |
| MousePheno | decreased circulating mineralocorticoid level | 1.75e-04 | 14 | 20 | 2 | MP:0003374 | |
| MousePheno | increased urine osmolality | 1.75e-04 | 14 | 20 | 2 | MP:0008055 | |
| MousePheno | increased circulating adrenocorticotropin level | 1.75e-04 | 14 | 20 | 2 | MP:0001748 | |
| MousePheno | decreased circulating aldosterone level | 1.75e-04 | 14 | 20 | 2 | MP:0002667 | |
| MousePheno | endometrium hyperplasia | 1.75e-04 | 14 | 20 | 2 | MP:0009092 | |
| MousePheno | increased brain size | 2.30e-04 | 85 | 20 | 3 | MP:0005238 | |
| MousePheno | abnormal adrenal gland zona fasciculata morphology | 3.28e-04 | 19 | 20 | 2 | MP:0008294 | |
| MousePheno | abnormal renin activity | 3.64e-04 | 20 | 20 | 2 | MP:0005581 | |
| MousePheno | increased adrenocorticotropin level | 4.42e-04 | 22 | 20 | 2 | MP:0005129 | |
| MousePheno | increased circulating renin level | 4.83e-04 | 23 | 20 | 2 | MP:0003352 | |
| MousePheno | oliguria | 5.27e-04 | 24 | 20 | 2 | MP:0003620 | |
| MousePheno | brain atrophy | 5.72e-04 | 25 | 20 | 2 | MP:0012506 | |
| MousePheno | hypotension | 7.19e-04 | 28 | 20 | 2 | MP:0001596 | |
| MousePheno | abnormal circulating renin level | 7.71e-04 | 29 | 20 | 2 | MP:0003349 | |
| MousePheno | increased liver weight | 8.53e-04 | 133 | 20 | 3 | MP:0002981 | |
| MousePheno | decreased urine output | 1.00e-03 | 33 | 20 | 2 | MP:0031358 | |
| MousePheno | enlarged adrenal glands | 1.06e-03 | 34 | 20 | 2 | MP:0000642 | |
| MousePheno | decreased thymus weight | 1.19e-03 | 36 | 20 | 2 | MP:0004956 | |
| MousePheno | abnormal circulating aldosterone level | 1.33e-03 | 38 | 20 | 2 | MP:0005346 | |
| MousePheno | abnormal circulating mineralocorticoid level | 1.33e-03 | 38 | 20 | 2 | MP:0003372 | |
| MousePheno | decreased fluid intake | 1.54e-03 | 41 | 20 | 2 | MP:0011942 | |
| MousePheno | abnormal aldosterone level | 1.54e-03 | 41 | 20 | 2 | MP:0011415 | |
| MousePheno | abnormal adrenocorticotropin level | 1.54e-03 | 41 | 20 | 2 | MP:0003966 | |
| MousePheno | abnormal pituitary gland size | 1.62e-03 | 42 | 20 | 2 | MP:0008936 | |
| MousePheno | abnormal adrenal cortex morphology | 1.62e-03 | 42 | 20 | 2 | MP:0008288 | |
| MousePheno | decreased circulating corticosterone level | 1.70e-03 | 43 | 20 | 2 | MP:0002665 | |
| MousePheno | abnormal brain size | 1.76e-03 | 375 | 20 | 4 | MP:0000771 | |
| MousePheno | decreased circulating glucocorticoid level | 1.77e-03 | 44 | 20 | 2 | MP:0003368 | |
| MousePheno | abnormal endometrium morphology | 2.20e-03 | 49 | 20 | 2 | MP:0004896 | |
| MousePheno | increased circulating glucocorticoid level | 2.38e-03 | 51 | 20 | 2 | MP:0003367 | |
| MousePheno | increased circulating corticosterone level | 2.38e-03 | 51 | 20 | 2 | MP:0001745 | |
| MousePheno | increased myocardial fiber size | 2.57e-03 | 53 | 20 | 2 | MP:0004564 | |
| MousePheno | decreased circulating potassium level | 2.66e-03 | 54 | 20 | 2 | MP:0005628 | |
| MousePheno | decreased urine osmolality | 2.66e-03 | 54 | 20 | 2 | MP:0002988 | |
| MousePheno | abnormal progesterone level | 2.66e-03 | 54 | 20 | 2 | MP:0011384 | |
| MousePheno | abnormal thymus weight | 3.28e-03 | 60 | 20 | 2 | MP:0004954 | |
| MousePheno | decreased circulating chloride level | 3.83e-03 | 65 | 20 | 2 | MP:0003020 | |
| MousePheno | abnormal urine osmolality | 3.83e-03 | 65 | 20 | 2 | MP:0002987 | |
| MousePheno | absent corpus luteum | 3.95e-03 | 66 | 20 | 2 | MP:0001134 | |
| MousePheno | abnormal liver weight | 4.23e-03 | 233 | 20 | 3 | MP:0004847 | |
| MousePheno | increased systemic arterial systolic blood pressure | 4.68e-03 | 72 | 20 | 2 | MP:0006144 | |
| MousePheno | enlarged uterus | 5.20e-03 | 76 | 20 | 2 | MP:0004906 | |
| MousePheno | enlarged liver | 5.32e-03 | 253 | 20 | 3 | MP:0000599 | |
| MousePheno | impaired swimming | 5.75e-03 | 80 | 20 | 2 | MP:0001522 | |
| Domain | Cyt_P450_mitochondrial | 1.20e-06 | 2 | 21 | 2 | IPR002399 | |
| Domain | NCD3G | 9.32e-05 | 13 | 21 | 2 | PF07562 | |
| Domain | GPCR_3_9-Cys_dom | 9.32e-05 | 13 | 21 | 2 | IPR011500 | |
| Domain | GPCR_3_CS | 1.09e-04 | 14 | 21 | 2 | IPR017979 | |
| Domain | GPCR_3 | 2.50e-04 | 21 | 21 | 2 | IPR000337 | |
| Domain | G_PROTEIN_RECEP_F3_4 | 2.74e-04 | 22 | 21 | 2 | PS50259 | |
| Domain | 7tm_3 | 2.74e-04 | 22 | 21 | 2 | PF00003 | |
| Domain | GPCR_3_C | 2.74e-04 | 22 | 21 | 2 | IPR017978 | |
| Domain | G_PROTEIN_RECEP_F3_2 | 2.74e-04 | 22 | 21 | 2 | PS00980 | |
| Domain | G_PROTEIN_RECEP_F3_3 | 2.74e-04 | 22 | 21 | 2 | PS00981 | |
| Domain | G_PROTEIN_RECEP_F3_1 | 2.74e-04 | 22 | 21 | 2 | PS00979 | |
| Domain | ANF_receptor | 7.83e-04 | 37 | 21 | 2 | PF01094 | |
| Domain | ANF_lig-bd_rcpt | 7.83e-04 | 37 | 21 | 2 | IPR001828 | |
| Domain | Peripla_BP_I | 8.70e-04 | 39 | 21 | 2 | IPR028082 | |
| Domain | Cyt_P450_CS | 1.60e-03 | 53 | 21 | 2 | IPR017972 | |
| Domain | CYTOCHROME_P450 | 1.85e-03 | 57 | 21 | 2 | PS00086 | |
| Domain | - | 1.92e-03 | 58 | 21 | 2 | 1.10.630.10 | |
| Domain | p450 | 1.92e-03 | 58 | 21 | 2 | PF00067 | |
| Domain | Cyt_P450 | 2.05e-03 | 60 | 21 | 2 | IPR001128 | |
| Domain | - | 5.05e-03 | 95 | 21 | 2 | 2.60.120.200 | |
| Domain | EGF | 8.72e-03 | 126 | 21 | 2 | PF00008 | |
| Domain | - | 1.33e-02 | 449 | 21 | 3 | 3.30.40.10 | |
| Domain | Znf_RING/FYVE/PHD | 1.41e-02 | 459 | 21 | 3 | IPR013083 | |
| Pathway | KEGG_MEDICUS_REFERENCE_STEROID_HORMONE_BIOSYNTHESIS_PROGESTERONE_TO_CORTISOL_CORTISONE | 1.21e-05 | 5 | 16 | 2 | M47522 | |
| Pathway | REACTOME_GLUCOCORTICOID_BIOSYNTHESIS | 5.41e-05 | 10 | 16 | 2 | M27076 | |
| Pathway | REACTOME_GLUCOCORTICOID_BIOSYNTHESIS | 6.60e-05 | 11 | 16 | 2 | MM14750 | |
| Pathway | REACTOME_MINERALOCORTICOID_BIOSYNTHESIS | 7.92e-05 | 12 | 16 | 2 | MM14749 | |
| Pathway | WP_GLUCOCORTICOID_BIOSYNTHESIS | 1.09e-04 | 14 | 16 | 2 | M46449 | |
| Pathway | WP_MINERALOCORTICOID_BIOSYNTHESIS | 1.09e-04 | 14 | 16 | 2 | M46453 | |
| Pathway | WP_CLASSICAL_PATHWAY_OF_STEROIDOGENESIS_WITH_GLUCOCORTICOID_AND_MINERALOCORTICOID_METABOLISM | 1.44e-04 | 16 | 16 | 2 | M39815 | |
| Pathway | REACTOME_ENDOGENOUS_STEROLS | 3.57e-04 | 25 | 16 | 2 | M11184 | |
| Pathway | REACTOME_ENDOGENOUS_STEROLS | 4.17e-04 | 27 | 16 | 2 | MM14844 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_GNAS_TO_ACTH_CORTISOL_SIGNALING_PATHWAY | 4.82e-04 | 29 | 16 | 2 | M47515 | |
| Pathway | KEGG_MEDICUS_VARIANT_CYP11B1_CYP11B2_FUSION_TO_ACTH_CORTISOL_SIGNALING_PATHWAY | 5.51e-04 | 31 | 16 | 2 | M47507 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ACTH_CORTISOL_SIGNALING_PATHWAY | 5.87e-04 | 32 | 16 | 2 | M47506 | |
| Pathway | REACTOME_METABOLIC_DISORDERS_OF_BIOLOGICAL_OXIDATION_ENZYMES | 6.63e-04 | 34 | 16 | 2 | M27461 | |
| Pathway | REACTOME_METABOLISM_OF_STEROID_HORMONES | 7.44e-04 | 36 | 16 | 2 | M27081 | |
| Pathway | REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS | 7.86e-04 | 37 | 16 | 2 | MM15067 | |
| Pathway | REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS | 8.73e-04 | 39 | 16 | 2 | M793 | |
| Pathway | REACTOME_METABOLISM_OF_STEROID_HORMONES | 9.65e-04 | 41 | 16 | 2 | MM14757 | |
| Pathway | WP_OXIDATION_BY_CYTOCHROME_P450 | 1.06e-03 | 43 | 16 | 2 | MM15873 | |
| Pathway | KEGG_STEROID_HORMONE_BIOSYNTHESIS | 1.73e-03 | 55 | 16 | 2 | M14933 | |
| Pathway | WP_OXIDATION_BY_CYTOCHROME_P450 | 2.20e-03 | 62 | 16 | 2 | M39653 | |
| Pathway | REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE | 2.34e-03 | 64 | 16 | 2 | M5650 | |
| Pathway | REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE | 2.48e-03 | 66 | 16 | 2 | MM14839 | |
| Pathway | REACTOME_G_ALPHA_I_SIGNALLING_EVENTS | 3.92e-03 | 289 | 16 | 3 | MM15057 | |
| Pubmed | A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis. | 8.83e-09 | 7 | 23 | 3 | 30692207 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17651452 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 22622494 | ||
| Pubmed | Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. | 4.18e-07 | 2 | 23 | 2 | 21519965 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 23150505 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 34743356 | ||
| Pubmed | Diagnosis of glucocorticoid-remediable aldosteronism in hypertensive children. | 4.18e-07 | 2 | 23 | 2 | 21625068 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 35012455 | ||
| Pubmed | Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production. | 4.18e-07 | 2 | 23 | 2 | 15062555 | |
| Pubmed | Role of genetic variation in regulation of aldosterone biosynthesis. | 4.18e-07 | 2 | 23 | 2 | 21164264 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 2783417 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 16110193 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 23761669 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 26066897 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17075030 | ||
| Pubmed | Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism. | 4.18e-07 | 2 | 23 | 2 | 2256920 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17075029 | ||
| Pubmed | Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). | 4.18e-07 | 2 | 23 | 2 | 2592361 | |
| Pubmed | Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism. | 4.18e-07 | 2 | 23 | 2 | 20339375 | |
| Pubmed | Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity. | 4.18e-07 | 2 | 23 | 2 | 15699546 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18162527 | ||
| Pubmed | CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity. | 4.18e-07 | 2 | 23 | 2 | 15507509 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 38341019 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 20708777 | ||
| Pubmed | Polymorphism of CYP11B2 determines salt sensitivity in Japanese. | 4.18e-07 | 2 | 23 | 2 | 17296872 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 23314847 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 17980006 | ||
| Pubmed | Association between aldosterone production and variation in the 11beta-hydroxylase (CYP11B1) gene. | 4.18e-07 | 2 | 23 | 2 | 16984984 | |
| Pubmed | Molecular genetic studies on the biosynthesis of aldosterone in humans. | 4.18e-07 | 2 | 23 | 2 | 22217843 | |
| Pubmed | Evidence for local aldosterone synthesis in the large intestine of the mouse. | 4.18e-07 | 2 | 23 | 2 | 35288482 | |
| Pubmed | Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. | 4.18e-07 | 2 | 23 | 2 | 15731365 | |
| Pubmed | Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. | 4.18e-07 | 2 | 23 | 2 | 18039983 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 20808686 | ||
| Pubmed | Mechanistic study of polychlorinated biphenyl 126-induced CYP11B1 and CYP11B2 up-regulation. | 4.18e-07 | 2 | 23 | 2 | 16396990 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 1741400 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 24837548 | ||
| Pubmed | Cyp11b1 null mouse, a model of congenital adrenal hyperplasia. | 4.18e-07 | 2 | 23 | 2 | 19029289 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 8645611 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 30046010 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 32540969 | ||
| Pubmed | Familial and phenotypic associations of the aldosterone Renin ratio. | 4.18e-07 | 2 | 23 | 2 | 19820005 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 26047574 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 26324851 | ||
| Pubmed | [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. | 4.18e-07 | 2 | 23 | 2 | 18397978 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 18651133 | ||
| Pubmed | Expression and localization of cytochrome P450(11beta,aldo) mRNA in the frog brain. | 4.18e-07 | 2 | 23 | 2 | 12231255 | |
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 1518866 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 7669222 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 20634641 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 22083159 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 1303253 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 15522937 | ||
| Pubmed | 4.18e-07 | 2 | 23 | 2 | 22933298 | ||
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 17984374 | ||
| Pubmed | Different isozymes of mouse 11 beta-hydroxylase produce mineralocorticoids and glucocorticoids. | 1.25e-06 | 3 | 23 | 2 | 1686470 | |
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 36861295 | ||
| Pubmed | Antiaging Gene Klotho Regulates Adrenal CYP11B2 Expression and Aldosterone Synthesis. | 1.25e-06 | 3 | 23 | 2 | 26471128 | |
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 21467193 | ||
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 36778748 | ||
| Pubmed | Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. | 1.25e-06 | 3 | 23 | 2 | 8111631 | |
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 2546938 | ||
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 2233742 | ||
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 16118390 | ||
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 33271253 | ||
| Pubmed | Mislocalization of protein kinase A drives pathology in Cushing's syndrome. | 1.25e-06 | 3 | 23 | 2 | 35830806 | |
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 28355486 | ||
| Pubmed | The prolactin regulatory element-binding regulates of the 11beta-hydroxylase gene. | 1.25e-06 | 3 | 23 | 2 | 18801336 | |
| Pubmed | Interaction of CYP11B1 (cytochrome P-45011 beta) with CYP11A1 (cytochrome P-450scc) in COS-1 cells. | 1.25e-06 | 3 | 23 | 2 | 10411633 | |
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 11932209 | ||
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 18974272 | ||
| Pubmed | Angiotensin II induces coordinated calcium bursts in aldosterone-producing adrenal rosettes. | 1.25e-06 | 3 | 23 | 2 | 32245948 | |
| Pubmed | Control of renin secretion from kidneys with renin cell hyperplasia. | 1.25e-06 | 3 | 23 | 2 | 24285498 | |
| Pubmed | 1.25e-06 | 3 | 23 | 2 | 7750493 | ||
| Pubmed | Single-Cell Resolution and Quantitation of Targeted Glucocorticoid Delivery in the Thymus. | 2.51e-06 | 4 | 23 | 2 | 30917317 | |
| Pubmed | β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer. | 2.51e-06 | 4 | 23 | 2 | 37129912 | |
| Pubmed | Zona Glomerulosa-Derived Klotho Modulates Aldosterone Synthase Expression in Young Female Mice. | 2.51e-06 | 4 | 23 | 2 | 38573585 | |
| Pubmed | 2.51e-06 | 4 | 23 | 2 | 8372604 | ||
| Pubmed | 2.51e-06 | 4 | 23 | 2 | 19342457 | ||
| Pubmed | 2.51e-06 | 4 | 23 | 2 | 29440508 | ||
| Pubmed | 2.51e-06 | 4 | 23 | 2 | 23303406 | ||
| Pubmed | Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. | 2.51e-06 | 4 | 23 | 2 | 32561853 | |
| Pubmed | Beta-Catenin Causes Adrenal Hyperplasia by Blocking Zonal Transdifferentiation. | 2.51e-06 | 4 | 23 | 2 | 32320669 | |
| Pubmed | Adrenal Abcg1 Controls Cholesterol Flux and Steroidogenesis. | 2.51e-06 | 4 | 23 | 2 | 38301271 | |
| Pubmed | 2.51e-06 | 4 | 23 | 2 | 37102205 | ||
| Pubmed | β-Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. | 2.51e-06 | 4 | 23 | 2 | 32245949 | |
| Pubmed | Calcineurin regulates aldosterone production via dephosphorylation of NFATC4. | 2.51e-06 | 4 | 23 | 2 | 37310791 | |
| Pubmed | 2.51e-06 | 4 | 23 | 2 | 11903322 | ||
| Pubmed | 4.18e-06 | 5 | 23 | 2 | 31398249 | ||
| Pubmed | Tissue kallikrein permits early renal adaptation to potassium load. | 4.18e-06 | 5 | 23 | 2 | 20624970 | |
| Pubmed | 4.18e-06 | 5 | 23 | 2 | 7590346 | ||
| Pubmed | 4.18e-06 | 5 | 23 | 2 | 7476975 | ||
| Pubmed | 4.18e-06 | 5 | 23 | 2 | 30580687 | ||
| Pubmed | Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells. | 4.18e-06 | 5 | 23 | 2 | 24035414 | |
| Pubmed | The Adrenal Clock Prevents Aberrant Light-Induced Alterations in Circadian Glucocorticoid Rhythms. | 4.18e-06 | 5 | 23 | 2 | 30321360 | |
| Pubmed | 6.26e-06 | 6 | 23 | 2 | 22580128 | ||
| Pubmed | Paracrine glucocorticoid activity produced by mouse thymic epithelial cells. | 6.26e-06 | 6 | 23 | 2 | 10224232 | |
| Pubmed | Expression of Cyp21a1 and Cyp11b1 in the fetal mouse testis. | 6.26e-06 | 6 | 23 | 2 | 17890294 | |
| Pubmed | 6.26e-06 | 6 | 23 | 2 | 10861000 | ||
| Pubmed | Structural and functional abnormalities in the spleen of an mFtz-F1 gene-disrupted mouse. | 8.77e-06 | 7 | 23 | 2 | 10029587 | |
| Pubmed | Aldo-keto reductase 1b7, a novel marker for renin cells, is regulated by cyclic AMP signaling. | 8.77e-06 | 7 | 23 | 2 | 26180185 | |
| Interaction | CYP11B1 interactions | 1.03e-05 | 5 | 21 | 2 | int:CYP11B1 | |
| Interaction | CYP11B2 interactions | 4.63e-05 | 10 | 21 | 2 | int:CYP11B2 | |
| GeneFamily | Cytochrome P450 family 11 | 2.20e-06 | 3 | 16 | 2 | 1007 | |
| GeneFamily | Ring finger proteins | 2.40e-02 | 275 | 16 | 2 | 58 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum_-18m-Lymphocytic-T_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.47e-05 | 160 | 22 | 3 | 97c899df1b57fd2bd1867e02bfedf1920c00ad17 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Cortical_Thick_Ascending_Limb_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 6.59e-05 | 161 | 22 | 3 | 4bb7bae54ba3bdf46b525c01f5ad3db8e49819cb | |
| ToppCell | healthy_donor-Myeloid-Monocytic-Developing_Neutrophil|healthy_donor / Disease condition, Lineage, Cell class and subclass | 7.74e-05 | 170 | 22 | 3 | cfd7f29805b7c51666b0eaf269c36c96b8765a1a | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_G2M|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.29e-05 | 174 | 22 | 3 | 7b2f35add804981c7d588a996bdbca6ec11a1ca5 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_4-Exc_L4-5_RORB_RPL31P31|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 9.17e-05 | 180 | 22 | 3 | b7513b9816a9cb9f3caaddb2a9fed0be1c7f9805 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_4|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 9.17e-05 | 180 | 22 | 3 | f96c5be4705e3d338c0393d2885ac8d5beccd6fd | |
| ToppCell | 3'_v3-blood-Hematopoietic_Erythro-Mega-Mega-Mast|blood / Manually curated celltypes from each tissue | 9.47e-05 | 182 | 22 | 3 | 1923b5669901f828e890416c22d1f1d21a4a2c6a | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.06e-04 | 189 | 22 | 3 | 8c8ca3b30d9be6c854615459a7bfba82b427c8bc | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.06e-04 | 189 | 22 | 3 | 5d902a4660a27548764bf04c6de152b565da835c | |
| ToppCell | PBMC-Severe-Myeloid-Neutrophil-Neutrophil-Neu_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.08e-04 | 190 | 22 | 3 | 3f0c7d130f66faea778fe567604edf1b4cdf85b3 | |
| ToppCell | PBMC-Severe-Myeloid-Neutrophil-Neutrophil-Neu_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.11e-04 | 192 | 22 | 3 | c09dcc73ff9c3855a0f3d7bfa0d5c99c09a117f2 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-2,_SCARA5-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.25e-04 | 200 | 22 | 3 | 0b2614b8513693dd508c9003699049efd9abac52 | |
| ToppCell | Neuronal-Excitatory-eB(RORB)-SEMA3E-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.25e-04 | 200 | 22 | 3 | 1a3d29a580d1b405a74869a1da3e818c581fc559 | |
| ToppCell | cellseq-Mesenchymal-Myocytic-Myocytic_2-SCMF|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.25e-04 | 200 | 22 | 3 | b441b3771fb7d9ee7b7a104afc35e466aace2da2 | |
| ToppCell | Neuronal-Excitatory-eB(RORB)-SEMA3E---L4-6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.25e-04 | 200 | 22 | 3 | 6f9ed8fe9cda91185c3a1a675353e11b8fec6ef1 | |
| ToppCell | Neuronal-Excitatory-eB(RORB)-SEMA3E--|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.25e-04 | 200 | 22 | 3 | 86705dfc05b3e1576543b93883c88fb55b742855 | |
| ToppCell | Neuronal-Excitatory-eB(RORB)-SEMA3E|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.25e-04 | 200 | 22 | 3 | db194b4f524fd008b3c5b4b6014b436190a1b87a | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX-Fibroblasts-2,_SCARA5|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 1.25e-04 | 200 | 22 | 3 | c338a08c1605527ab9aaf62ea151a19e8469dc6d | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-2,_SCARA5|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.25e-04 | 200 | 22 | 3 | 8d2ceb2080c67b20f452eeca605aa27a58033c04 | |
| Drug | cyadox | 7.33e-07 | 2 | 20 | 2 | ctd:C020728 | |
| Drug | 18-hydroxydeoxycorticosterone | 7.33e-07 | 2 | 20 | 2 | ctd:C042509 | |
| Drug | 18-hydroxycortisol | 2.20e-06 | 3 | 20 | 2 | ctd:C033689 | |
| Drug | C05489 | 4.39e-06 | 4 | 20 | 2 | CID000440708 | |
| Drug | 17alpha, 21-dihydroxypregnenolone | 7.32e-06 | 5 | 20 | 2 | CID000192735 | |
| Drug | Methandrostenolone | 1.10e-05 | 6 | 20 | 2 | ctd:D008696 | |
| Drug | Tetrahydronaphthalenes | 1.10e-05 | 6 | 20 | 2 | ctd:D013764 | |
| Drug | Cortodoxone | 1.54e-05 | 7 | 20 | 2 | ctd:D003350 | |
| Drug | NSC-4928 | 1.73e-05 | 58 | 20 | 3 | CID000221086 | |
| Drug | 2,2',3,3',4,6'-hexachlorobiphenyl | 2.05e-05 | 8 | 20 | 2 | ctd:C094859 | |
| Drug | Mesalamine [89-57-6]; Up 200; 26.2uM; MCF7; HT_HG-U133A | 2.46e-05 | 199 | 20 | 4 | 7241_UP | |
| Drug | 2,2',3,4',5',6-hexachlorobiphenyl | 2.63e-05 | 9 | 20 | 2 | ctd:C120129 | |
| Drug | GKT137831 | 2.63e-05 | 9 | 20 | 2 | ctd:C576694 | |
| Drug | synthetic pyrethrins | 3.19e-05 | 71 | 20 | 3 | CID000002982 | |
| Drug | Indans | 3.28e-05 | 10 | 20 | 2 | ctd:D007189 | |
| Drug | perflubron | 3.28e-05 | 10 | 20 | 2 | ctd:C003072 | |
| Drug | fludrocortisone | 3.91e-05 | 76 | 20 | 3 | CID000031378 | |
| Drug | AC1L2NX7 | 4.01e-05 | 11 | 20 | 2 | CID000125056 | |
| Drug | 2,3,3',4,4',5-hexachlorobiphenyl | 4.01e-05 | 11 | 20 | 2 | ctd:C087667 | |
| Drug | CB149 | 4.81e-05 | 12 | 20 | 2 | CID000038016 | |
| Drug | 3,4,5,3',4',5'-hexachlorobiphenyl | 5.68e-05 | 13 | 20 | 2 | ctd:C027309 | |
| Drug | 1H,1H,2H,2H-perfluorodecanol | 5.68e-05 | 13 | 20 | 2 | ctd:C033729 | |
| Drug | tienilic acid | 7.15e-05 | 93 | 20 | 3 | CID000038409 | |
| Drug | dalcetrapib | 7.64e-05 | 15 | 20 | 2 | ctd:C411602 | |
| Drug | 1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene | 8.73e-05 | 16 | 20 | 2 | ctd:C055238 | |
| Drug | 3',4'-dimethoxyflavone | 8.73e-05 | 16 | 20 | 2 | ctd:C509288 | |
| Drug | Fadrozole | 9.89e-05 | 17 | 20 | 2 | ctd:D017316 | |
| Drug | synephrine | 1.11e-04 | 18 | 20 | 2 | CID000007172 | |
| Drug | anacetrapib | 1.24e-04 | 19 | 20 | 2 | ctd:C530884 | |
| Drug | tetrahydroaldosterone | 1.38e-04 | 20 | 20 | 2 | CID000122135 | |
| Drug | 11 alpha-hydroxyprogesterone | 1.38e-04 | 20 | 20 | 2 | CID000092730 | |
| Drug | clofibrate | 1.39e-04 | 311 | 20 | 4 | CID000002796 | |
| Drug | 4-androsten-11 beta-ol-3,17-dione | 1.52e-04 | 21 | 20 | 2 | CID000094141 | |
| Drug | tetrahydrocortisone | 1.68e-04 | 22 | 20 | 2 | CID000005866 | |
| Drug | Proanthocyanidins | 2.00e-04 | 24 | 20 | 2 | ctd:D044945 | |
| Drug | 18-hydroxydeoxycorticosterone | 2.17e-04 | 25 | 20 | 2 | CID000064970 | |
| Drug | benidipine | 2.54e-04 | 27 | 20 | 2 | ctd:C061004 | |
| Drug | 18-oxocortisol | 2.73e-04 | 28 | 20 | 2 | CID000123712 | |
| Drug | tetrahydrodeoxycortisol | 3.36e-04 | 31 | 20 | 2 | CID000010593 | |
| Drug | AC1L3X1Y | 3.36e-04 | 31 | 20 | 2 | CID000123655 | |
| Drug | haloperidol | 3.44e-04 | 394 | 20 | 4 | CID000003559 | |
| Drug | Mequindox | 3.58e-04 | 32 | 20 | 2 | ctd:C545385 | |
| Drug | walrycin A | 3.58e-04 | 32 | 20 | 2 | ctd:C574123 | |
| Drug | 17-isoprogesterone | 3.78e-04 | 1170 | 20 | 6 | CID000004920 | |
| Drug | Metyrapone | 4.04e-04 | 34 | 20 | 2 | ctd:D008797 | |
| Drug | nifedipine | 4.18e-04 | 415 | 20 | 4 | CID000004485 | |
| Drug | luliconazole | 4.29e-04 | 35 | 20 | 2 | CID003003141 | |
| Drug | CPAs | 4.29e-04 | 35 | 20 | 2 | CID000016770 | |
| Drug | 21-deoxycortisol | 5.33e-04 | 39 | 20 | 2 | CID000092827 | |
| Drug | APAs | 5.33e-04 | 39 | 20 | 2 | CID000004649 | |
| Drug | LS-63783 | 5.40e-04 | 804 | 20 | 5 | CID000000231 | |
| Drug | Gramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A | 6.05e-04 | 192 | 20 | 3 | 2799_UP | |
| Drug | Amethopterin (R,S) [59-05-2]; Down 200; 8.8uM; HL60; HG-U133A | 6.05e-04 | 192 | 20 | 3 | 1599_DN | |
| Drug | Prochlorperazine dimaleate [84-02-6]; Down 200; 6.6uM; PC3; HT_HG-U133A | 6.05e-04 | 192 | 20 | 3 | 6664_DN | |
| Drug | LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A | 6.15e-04 | 193 | 20 | 3 | 6956_DN | |
| Drug | 18-hydroxycorticosterone | 6.18e-04 | 42 | 20 | 2 | CID000011222 | |
| Drug | (+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; MCF7; HT_HG-U133A | 6.24e-04 | 194 | 20 | 3 | 3384_DN | |
| Drug | Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 6.24e-04 | 194 | 20 | 3 | 4961_UP | |
| Drug | Fludrocortisone acetate [514-36-3]; Up 200; 9.4uM; PC3; HT_HG-U133A | 6.24e-04 | 194 | 20 | 3 | 3785_UP | |
| Drug | estradiol, USP; Up 200; 0.1uM; MCF7; HT_HG-U133A | 6.33e-04 | 195 | 20 | 3 | 5568_UP | |
| Drug | Thalidomide [50-35-1]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 6.33e-04 | 195 | 20 | 3 | 5990_UP | |
| Drug | Ribostamycin sulfate salt [53797-35-6]; Up 200; 7.2uM; HL60; HT_HG-U133A | 6.33e-04 | 195 | 20 | 3 | 2705_UP | |
| Drug | Bromperidol [10457-90-6]; Down 200; 9.6uM; HL60; HG-U133A | 6.33e-04 | 195 | 20 | 3 | 1723_DN | |
| Drug | Pantothenic acid calcium salt monohydrate [63409-48-3]; Down 200; 8uM; MCF7; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 3248_DN | |
| Drug | Pivmecillinam hydrochloride [32887-03-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 6014_DN | |
| Drug | F0447-0125; Up 200; 10uM; MCF7; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 6396_UP | |
| Drug | DNA-PK Inhibitor III; Down 200; 1uM; MCF7; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 7513_DN | |
| Drug | Bz alpha GalNAc | 6.48e-04 | 43 | 20 | 2 | CID000122253 | |
| Drug | CP-319743 [172078-87-4]; Down 200; 10uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 7486_DN | |
| Drug | AC1Q6O8T | 6.52e-04 | 197 | 20 | 3 | CID000002193 | |
| Drug | (-)-Cinchonidine [485-71-2]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 2772_DN | |
| Drug | Acyclovir [59277-89-3]; Up 200; 17.8uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 5643_UP | |
| Drug | Amoxapine [14028-44-5]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 1513_UP | |
| Drug | Deoxycorticosterone [64-85-7]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 6.62e-04 | 198 | 20 | 3 | 6476_UP | |
| Drug | tolbutamide | 6.62e-04 | 198 | 20 | 3 | CID000005505 | |
| Drug | Ketorolac tromethamine [74103-07-4]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 6.62e-04 | 198 | 20 | 3 | 6489_DN | |
| Drug | Pronethalol hydrochloride [51-02-5]; Up 200; 15uM; HL60; HT_HG-U133A | 6.62e-04 | 198 | 20 | 3 | 2902_UP | |
| Drug | Tolnaftate [2398-96-1]; Up 200; 13uM; HL60; HG-U133A | 6.72e-04 | 199 | 20 | 3 | 2001_UP | |
| Drug | Diflunisal [22494-42-4]; Down 200; 16uM; PC3; HT_HG-U133A | 6.72e-04 | 199 | 20 | 3 | 4210_DN | |
| Drug | Neomycin sulfate [1405-10-3]; Down 200; 4.2uM; HL60; HG-U133A | 6.72e-04 | 199 | 20 | 3 | 1383_DN | |
| Drug | Clopamide [636-54-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 6.72e-04 | 199 | 20 | 3 | 3220_UP | |
| Drug | Palmatine chloride [3486-67-7]; Up 200; 10.4uM; PC3; HT_HG-U133A | 6.72e-04 | 199 | 20 | 3 | 6612_UP | |
| Drug | Artemisinin [63968-64-9]; Up 200; 14.2uM; MCF7; HT_HG-U133A | 6.82e-04 | 200 | 20 | 3 | 7007_UP | |
| Drug | Minoxidil [38304-91-5]; Down 200; 19.2uM; PC3; HG-U133A | 6.82e-04 | 200 | 20 | 3 | 1914_DN | |
| Drug | THDOC | 7.09e-04 | 45 | 20 | 2 | CID000091475 | |
| Drug | Androstenedione | 7.09e-04 | 45 | 20 | 2 | ctd:D000735 | |
| Drug | Desoxycorticosterone | 7.74e-04 | 47 | 20 | 2 | ctd:D003900 | |
| Drug | hexanal | 7.74e-04 | 47 | 20 | 2 | CID000006184 | |
| Drug | tetrahydrocortisol | 8.07e-04 | 48 | 20 | 2 | CID000005864 | |
| Drug | enniatins | 8.07e-04 | 48 | 20 | 2 | ctd:C100264 | |
| Drug | AC1NB8R3 | 8.18e-04 | 213 | 20 | 3 | CID004489307 | |
| Drug | oxygen | 8.36e-04 | 499 | 20 | 4 | CID000000977 | |
| Drug | diisononyl phthalate | 8.76e-04 | 50 | 20 | 2 | ctd:C012125 | |
| Disease | adrenal cortical adenoma (is_marker_for) | 4.82e-07 | 2 | 21 | 2 | DOID:0050891 (is_marker_for) | |
| Disease | Glucocorticoid-remediable aldosteronism | 4.82e-07 | 2 | 21 | 2 | C1260386 | |
| Disease | congenital adrenal hyperplasia (implicated_via_orthology) | 1.45e-06 | 3 | 21 | 2 | DOID:0050811 (implicated_via_orthology) | |
| Disease | clinical treatment | 3.25e-06 | 41 | 21 | 3 | EFO_0007056 | |
| Disease | primary hyperaldosteronism (is_implicated_in) | 4.82e-06 | 5 | 21 | 2 | DOID:446 (is_implicated_in) | |
| Disease | Hyperaldosteronism | 7.22e-06 | 6 | 21 | 2 | C0020428 | |
| Disease | Conn Syndrome | 7.22e-06 | 6 | 21 | 2 | C1384514 | |
| Disease | protocadherin alpha-7 measurement | 1.01e-05 | 7 | 21 | 2 | EFO_0801973 | |
| Disease | protein FAM163B measurement | 1.73e-05 | 9 | 21 | 2 | EFO_0802936 | |
| Disease | androstenedione measurement | 2.16e-05 | 10 | 21 | 2 | EFO_0007972 | |
| Disease | cell growth regulator with EF hand domain protein 1 measurement | 2.64e-05 | 11 | 21 | 2 | EFO_0801461 | |
| Disease | 3-hydroxyanthranilate 3,4-dioxygenase measurement | 2.64e-05 | 11 | 21 | 2 | EFO_0021862 | |
| Disease | hypertension (implicated_via_orthology) | 1.00e-04 | 128 | 21 | 3 | DOID:10763 (implicated_via_orthology) | |
| Disease | apolipoprotein L1 measurement | 1.43e-04 | 25 | 21 | 2 | EFO_0021854 | |
| Disease | brain infarction (biomarker_via_orthology) | 2.51e-04 | 33 | 21 | 2 | DOID:3454 (biomarker_via_orthology) | |
| Disease | Calcium channel blocker use measurement | 4.48e-04 | 213 | 21 | 3 | EFO_0009930 | |
| Disease | hypertension (biomarker_via_orthology) | 5.39e-04 | 227 | 21 | 3 | DOID:10763 (biomarker_via_orthology) | |
| Disease | complement factor H-related protein 1 measurement | 7.26e-04 | 56 | 21 | 2 | EFO_0600054 | |
| Disease | Alcoholic Intoxication, Chronic | 8.73e-04 | 268 | 21 | 3 | C0001973 | |
| Disease | axial length measurement | 1.37e-03 | 77 | 21 | 2 | EFO_0005318 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| HDGRCYQSWDDFICY | 551 | P78357 | |
| LNEDWYHQSYDCVCV | 866 | P51828 | |
| ANLCDDRYNWCYHTE | 96 | Q8NE62 | |
| WHCERCEGYNYQVDE | 536 | O00222 | |
| WCDTINNRAYCHYDG | 1741 | Q9BXP8 | |
| HFEAWDCIFQYGDNC | 256 | P15538 | |
| WCYCHYCNLELDIRD | 141 | A0A1B0GTR0 | |
| CYDTYGADIDCQWID | 351 | P28300 | |
| DYEYCCPCEWHRTEH | 291 | Q17RS7 | |
| HFEAWDCIFQYGDNC | 256 | P19099 | |
| CFVYDQTHSNCRDYW | 86 | P60507 | |
| AQAGDEADYYCQVWD | 96 | A0A075B6K5 | |
| YWRQGCYPNVCDDDQ | 446 | Q96CW9 | |
| VCANWDFECDYGYER | 746 | Q9UPU3 | |
| HFAVCYRCAQGEYWD | 326 | B7ZBB8 | |
| EHENNNRFEEYEWCG | 346 | Q5VTB9 | |
| WWDHDCQRRLYYVCE | 306 | Q9Y240 | |
| YNVCDYQCWENSVGE | 411 | Q8IU68 | |
| RENGYECEWRYNSCA | 1136 | P04275 | |
| DEYECQACPNNEWSY | 531 | Q8TE23 | |
| LCNNNDEEDLYEYGW | 106 | Q9ULT6 | |
| EAQEYELCEEWGCLY | 1556 | Q68DK2 | |
| NYTEYDCNRNEVCWP | 636 | Q96GX1 |